Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 4 Univariate and multivariate analyses of the prognostic factors for progression-free survival

Factors	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
AFP (≤ 1210 vs > 1210)	0.71 (0.46- 1.09)	0.121	-	-
Age (≥ 60 yr vs < 60 yr)	1.00 (0.65- 1.53)	0.984	-	-
Alcohol (Yes vs No)	0.93 (0.60- 1.45)	0.753	-	-
ALT (≤ 40 vs No)	0.81 (0.53- 1.24)	0.337	-	-
Antiviral therapy (Yes vs No)	0.61 (0.32- 1.16)	0.132	-	-
BCLC stage (C vs B)	0.55 (0.35 - 0.87)	0.011	0.57 (0.36-0.91)	0.017
BMI (Normal vs Low)	1.35 (0.61- 3.00)	0.457	-	-
BMI (Over obese vs Low)	0.46 (0.16- 1.31)	0.146	-	-
BMI (Weight vs Low)	0.87 (0.53- 1.44)	0.584	-	-
Child Pugh score (B vs C)	1.34 (0.86- 2.06)	0.192	-	-
Diabetes (Yes vs No)	1.02 (0.62 - 1.69)	0.929	-	-
Cirrhosis (Yes vs No)	0.99 (0.64- 1.52)	0.955	-	-
ECOG (2 vs 0-1)	1.92 (1.25- 2.96)	0.003	1.86 (1.21-2.86)	0.005
HBV (Positive vs Negative)	1.21 (0.76- 1.94)	0.417	-	-
HBV-DNA (HBV ≤ 2000 vs HBV > 2000)	1.04 (0.67- 1.60)	0.877	-	-
Hypertensive (Yes vs No)	0.97 (0.60- 1.56)	0.904	-	-
PVTT (Yes vs No)	1.36 (0.86- 2.13)	0.186	-	-
Post operative (Yes vs No)	0.78 (0.50- 1.22)	0.284	-	-
Metastasis (Yes vs No)	0.73 (0.47- 1.14)	0.164	-	-
Sex (male vs No)	0.83 (0.54- 1.28)	0.395	-	-
Smoking (Yes vs No)	0.95 (0.59- 1.53)	0.834	-	-
Total bilirubin (≤ 34 vs > 34)	0.92 (0.57- 1.48)	0.726	-	-
Virus reactivation (Yes vs No)	1.30 (0.18- 9.43)	0.798	-	-

HBV: Hepatitis B virus; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; PVTT: Portal vein tumor thrombosis.